IEO, European Institute of Oncology, Melanoma Division, Via G. Ripamonti 435, 20141 Milan, Italy.
Expert Opin Biol Ther. 2011 Oct;11(10):1395-407. doi: 10.1517/14712598.2011.605353. Epub 2011 Jul 30.
Tumor-derived heat shock protein (HSP)-peptide complexes (HSPPCs) induced immunity against malignancies in preclinical trials, working across tumor types and bypassing the need to identify single immunogenic peptides. These results paved the way for the use of human gp96 obtained from autologous tumor samples as an anti-cancer vaccine.
Autologous tumor-derived HSP gp96 peptide complex (HSPPC-96) vaccine is emerging as a tumor- and patient-specific cancer vaccine, with confirmed activity in several malignancies. It has been tested in Phase III clinical trials in advanced melanoma and kidney cancer with evidence for efficacy in patients with earlier stage disease. HSPPC-96-based vaccine demonstrated an excellent safety profile, thus emerging as a novel therapeutic approach with a suggestive role in cancer therapy. This review summarizes work on the use of HSPPC-96 as an autologous anti-tumor vaccine in advanced melanoma. Data were retrieved by PubMed and Medline research and using the authors' personal experience.
Further investigations are needed to understand the biological basis of immune functions in order to improve the clinical outcome of HSP-based cancer therapy. In the near future, the combination of HSP-based vaccines with other biological compounds might represent a successful strategy in the therapy of advanced melanoma.
在临床前试验中，肿瘤来源的热休克蛋白（HSP）-肽复合物（HSPPCs）诱导了对恶性肿瘤的免疫反应，其作用跨越了肿瘤类型，并且无需鉴定单一的免疫原性肽。这些结果为使用从自体肿瘤样本中获得的人 gp96 作为抗癌疫苗铺平了道路。
自体肿瘤衍生的 HSP gp96 肽复合物（HSPPC-96）疫苗作为一种肿瘤和患者特异性的癌症疫苗正在出现，在几种恶性肿瘤中已被证实具有活性。它已在晚期黑色素瘤和肾癌的 III 期临床试验中进行了测试，并且在早期疾病患者中具有疗效的证据。HSPPC-96 为基础的疫苗表现出极好的安全性，因此作为一种新的治疗方法出现，对癌症治疗具有提示作用。这篇综述总结了 HSPPC-96 作为晚期黑色素瘤自体抗肿瘤疫苗的应用。通过 PubMed 和 Medline 研究以及作者的个人经验检索了数据。
需要进一步研究以了解免疫功能的生物学基础，从而提高基于 HSP 的癌症治疗的临床效果。在不久的将来，将 HSP 为基础的疫苗与其他生物化合物结合可能是治疗晚期黑色素瘤的一种成功策略。
